Director at Collegium (NASDAQ: COLL) awarded 8,741 RSUs in equity grant

Rhea-AI Filing Summary

SANTINI GINO reported acquisition or exercise transactions in this Form 4 filing.

COLLEGIUM PHARMACEUTICAL director Gino Santini received an equity award of 8,741 restricted stock units (RSUs) of common stock on May 14, 2026. Each RSU represents one share of common stock at no purchase price.

The RSUs vest on the earlier of May 14, 2027, or the company’s 2027 Annual Meeting of Shareholders, if he continues serving as a director. Settlement can occur then or, if he elects, at the end of his board service, upon death or disability, or upon a change in control. Following this grant, he directly holds 103,783 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SANTINI GINO

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	8,741	$0.00	--

Holdings After Transaction: Common Stock — 103,783 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 8,741 units Grant price: $0.0000 per share Post-grant holdings: 103,783 shares +1 more

4 metrics

RSU grant size 8,741 units Restricted stock units granted on May 14, 2026

Grant price $0.0000 per share RSU award issued at no cash cost

Post-grant holdings 103,783 shares Common stock directly owned after the transaction

Vesting date May 14, 2027 Or earlier 2027 Annual Meeting of Shareholders

Key Terms

restricted stock units ("RSUs"), Annual Meeting of Shareholders, change in control

3 terms

restricted stock units ("RSUs") financial

"Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Annual Meeting of Shareholders financial

"The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

change in control financial

"on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SANTINI GINO

(Last) (First) (Middle)

C/O COLLEGIUM PHARMACEUTICAL, INC.

100 TECHNOLOGY CENTER DRIVE

(Street)

STOUGHTON MASSACHUSETTS 02072

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
COLLEGIUM PHARMACEUTICAL, INC [ COLL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A(1)		8,741	A	$0	103,783	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

	/s/ Colleen Tupper as Attorney-in-Fact for Gino Santini	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Collegium Pharmaceutical (COLL) disclose for director Gino Santini?

Collegium Pharmaceutical reported a grant of 8,741 restricted stock units to director Gino Santini. This is a stock-based compensation award, not an open-market share purchase or sale, and reflects routine director equity compensation at no cash cost to him.

How many restricted stock units were granted to the Collegium (COLL) director and what do they represent?

The director received 8,741 restricted stock units, each representing the right to one share of Collegium common stock. These units convert into actual shares when they vest and are settled, providing equity-based compensation aligned with shareholder interests over time.

When do the newly granted RSUs for the Collegium (COLL) director vest?

The RSUs vest on the earlier of May 14, 2027, or Collegium’s 2027 Annual Meeting of Shareholders. Vesting is conditioned on the director’s continued board service, aligning the award with ongoing governance responsibilities and long-term company performance.

Is the Collegium (COLL) director’s RSU grant an open-market stock purchase?

No, the RSU grant is a compensation award with a zero-dollar grant price, not an open-market purchase. The director does not pay cash to acquire these units; instead, they vest over time and settle into shares according to the award’s terms.

How many Collegium (COLL) shares does the director hold after this RSU grant?

After the grant, the director is reported as directly holding 103,783 shares of Collegium common stock. This figure includes the impact of the newly awarded RSUs as shown in the filing’s post-transaction ownership line for his direct holdings.

Under what circumstances can the Collegium (COLL) RSUs be settled earlier than the scheduled vesting?

Settlement may occur earlier if the director elects deferral and then his board service ends, or upon his death, disability, or a change in control of Collegium. In each case, the RSUs are settled in shares of common stock under the plan terms.